trial

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

NCTId NCT00159770
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 290
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
290
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2001-11
Primary completion
—
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
OlanzapinePanss , CGI-C, UKU-SERS-PaBlood tests

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

43 total
Aalborg, DenmarkArhus C, DenmarkAugustenborg, DenmarkBallerup Municipality, DenmarkBrovst, DenmarkCopenhagen, DenmarkDianalund, DenmarkEsbjerg, DenmarkEsbjerg N, DenmarkGlostrup Municipality, DenmarkHaderslev, DenmarkHolbæk, Denmark

Facts & assertions

3 sourced
Enrollment
290
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Panss , CGI-C, UKU-SERS-Pa
drug
Blood tests
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication